Real-World Safety Profile of Proton Pump Inhibitors in Infants as Reported in the FDA Adverse Event Reporting System (FAERS): Tiny Tummies, Key Decisions

<b>Background</b>: Proton pump inhibitors (PPIs) are widely used for gastric acid suppression, yet their efficacy and safety in neonates and infants remain unclear. While esomeprazole is the only Food and Drug Administration (FDA)-approved PPI for neonates and infants under 1 year of age...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hülya Tezel Yalçın, Nadir Yalçın, Karel Allegaert
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Pharmaceuticals
Subjects:	drug safety adverse drug event medication error neonates infants acid reducers
Online Access:	https://www.mdpi.com/1424-8247/18/5/730
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Drug Safety During Breastfeeding: A Comparative Analysis of FDA Adverse Event Reports and LactMed<sup>®</sup>
by: Hülya Tezel Yalçın, et al.
Published: (2024-12-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Lin Y, et al.
Published: (2025-06-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

Gender differences in drug-induced precocious puberty: a real-world analysis of adverse event reports from the FDA FAERS database (2004–2024)
by: Bangguo Song, et al.
Published: (2025-07-01)

Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
by: Lele Ge, et al.
Published: (2025-05-01)

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System
by: Hao Zhu, et al.
Published: (2025-03-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study
by: Jingkai Di, et al.
Published: (2025-07-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

PHARMACOVİGİLANCE OF DRUG-INDUCED LEUKEMİA: A DESCRİPTİVE STUDY OF FDA ADVERSE EVENT REPORTİNG SYSTEM FROM 1969-2024
by: Ahmet Sarici, et al.
Published: (2024-12-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Potential adverse events of fluoxetine: a real-world study based on the FAERS database
by: Xuezheng Gao, et al.
Published: (2025-07-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

METHOTREXATE AND PROTON PUMP INHIBITORS: ARE THERE ANY NEGATIVE PHARMACOLOGIAL EFFECTS?
by: Andrey E Karateev, et al.
Published: (2014-02-01)

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database
by: Fengqi Zhou, et al.
Published: (2025-02-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil
by: Yun Li, et al.
Published: (2025-01-01)

A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system
by: Yong Yu, et al.
Published: (2025-02-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database
by: Xiang Li, et al.
Published: (2025-04-01)

Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database
by: Fengqi Zhou, et al.
Published: (2025-04-01)

Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system
by: Guihao Zheng, et al.
Published: (2025-07-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System
by: Yi Zhang, et al.
Published: (2025-07-01)

Spontaneous Adverse Drug Reaction Reporting of Congenital Malformations: A Danish National Register Study
by: Ulrik Lausten-Thomsen, et al.
Published: (2025-06-01)

Evaluation and study of adverse reactions to imiglucerase based on the FAERS database
by: Pan Hong, et al.
Published: (2025-08-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
by: Linlin Yan, et al.
Published: (2025-04-01)

A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database
by: Hesen Huang, et al.
Published: (2025-07-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
by: Shaimaa Elshafie, et al.
Published: (2025-01-01)

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-06-01)